The subscription price upon exercise of warrants of series TO2A in aXichem AB (publ) ("aXichem" or the "Company"), which were issued as part of the rights issue announced on 3 February 2026 as well as the subsequent directed issue to a guarantor announced on 10 March 2026, has been set at SEK 1.50. The subscription price corresponds to 70 percent of the Company's share's volume-weighted average price on Nasdaq First North Growth Market during the period 31 August 2026 up to and including 4 September 2026.
The warrants of series TO2A can be exercised during the period from and including 7 September 2026 up to and including 18 September 2026 to subscribe for new Class A shares in the Company at a subscription price of SEK 1.50 per share. Holders of warrants of series TO2A who do not intend to exercise these to subscribe for new Class A shares can sell the warrants of series TO2A on Nasdaq First North Growth Market up to and including 16 September 2026. Warrants of series TO2A that are neither sold nor exercised for subscription of new Class A shares expire without value after 18 September 2026. Please note that some nominees may close their application earlier than 18 September 2026.
Summarized terms and conditions for the warrants of series TO2A
Exercise period: 7 – 18 September 2026.
Issue volume: 8,614,216 warrants of series TO2A, which entitle to subscription for 8,614,216 new Class A shares in the Company. Upon full exercise, the Company will receive approximately SEK 12.9 million before issue costs.
Subscription price: SEK 1.50 per share.
Last day of trading in warrants of series TO2A: 16 September 2026.
Complete terms and conditions for the warrants of series TO2A are available on the Company's website www.axichem.com.
Advisors
Västra Hamnen Corporate Finance AB is acting as financial advisor and Advokatfirman Lindahl is acting as legal advisor to aXichem regarding the warrants of series TO2A. Nordic Issuing is acting as issuing agent.
The certified adviser for aXichem is Västra Hamnen Corporate Finance AB.
The information was submitted for publication, through the agency of the contact person set out below, CEST on 4 September 2026, at 18:30 CET.
Company contact: Torsten Helsing, CEO, aXichem AB
Phone: +46 40 121 355. Email: torsten.helsing@axichem.com
About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: ingredient in animal feed for poultry and ruminants, ingredient in dietary supplements for intestinal health, weight control, sports and exercise, and as an ingredient in dietary supplements for bioavailability enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB. More information is available at www.axichem.com.
